Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion
The novel coronavirus (COVID-19) has continued its global spread since the first documented case in late 2019 in Wuhan, China. With over 10 million cases and 500 thousand deaths reported worldwide, the need for an effective treatment regimen is evident. Historically, convalescent plasma (CP) has bee...
Main Authors: | Ryan M. Farhat, Mohammad A. Mousa, Eshaan J. Daas, Marilyn K. Glassberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2020.00435/full |
Similar Items
-
Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study
by: Li Huang, et al.
Published: (2021-08-01) -
A Retrospective Survey among SARS-CoV-1 Infected Healthcare Workers after Three Years Post-Infection
by: Szu-Wei Huang, et al.
Published: (2021-08-01) -
Convalescent plasma: A potential therapeutic option for COVID-19 patients
by: Swee Li Ng, et al.
Published: (2020-01-01) -
Challenges and future directions of potential natural products leads against 2019-nCoV outbreak
by: Meirambek Ospanov, et al.
Published: (2020-12-01) -
SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
by: Hatem A. Elshabrawy
Published: (2020-06-01)